Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Revealing the Hidden Tube: A Simple Laser Solution in a Complex Eye.

Ophthalmology. Glaucoma·2026
Same author

Rho-kinase inhibitors predisposing to secondary keratitis.

BMJ case reports·2026
Same author

Diffuse Choroidal Hemangioma in Sturge-Weber Syndrome: Correlation between Clinical Features, Imaging, and Treatment Response.

Ocular oncology and pathology·2026
Same author

Long-term Clinical Outcomes of Type 1 Keratoprosthesis: A 10-Year Experience.

Cornea·2026
Same author

Early-Onset Normal-Tension Glaucoma in Patients Under 40 Years of Age: Risk Factors for Progression.

Cureus·2026
Same author

<i>ASPH-</i>related ectopia lentis revisited: genetic variability, clinical diversity, and evolving therapeutic approaches.

Ophthalmic genetics·2026

Related Experiment Video

Updated: May 14, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

Treatment outcomes in malignant glaucoma.

Paaraj Dave1, Sirisha Senthil, Harsha L Rao

  • 1LV Prasad Eye Institute, Hyderabad, India.

Ophthalmology
|February 5, 2013
PubMed
Summary

Successful management of malignant glaucoma (MG) is achievable with timely interventions. A stepladder treatment approach, including medical therapy, laser hyaloidotomy, vitrectomy, and cyclophotocoagulation, demonstrated a 96% resolution rate in this study.

Related Experiment Videos

Last Updated: May 14, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

Area of Science:

  • Ophthalmology
  • Glaucoma Research
  • Surgical Outcomes

Background:

  • Malignant glaucoma (MG) is a rare, severe form of secondary angle-closure glaucoma.
  • It can occur after intraocular surgery, particularly in eyes with pre-existing risk factors.
  • Understanding effective treatment strategies is crucial for managing this challenging condition.

Purpose of the Study:

  • To evaluate the treatment outcomes for malignant glaucoma.
  • To assess the efficacy of a stepwise treatment algorithm in resolving malignant glaucoma.
  • To identify specific interventions beneficial for different patient subgroups.

Main Methods:

  • Retrospective case series of 28 eyes from 26 patients diagnosed with malignant glaucoma between 1991 and 2009.
  • Diagnosis criteria included shallow anterior chamber, patent iridotomy, and elevated intraocular pressure (IOP) post-surgery.
  • Treatment involved a tiered approach: medical therapy/cycloplegics, laser hyaloidotomy, vitrectomy-hyaloidotomy-iridectomy (VHI), or transscleral cyclophotocoagulation (TSCPC).

Main Results:

  • A 96% resolution rate (27/28 eyes) was achieved.
  • Mean IOP decreased significantly from 34 mmHg to 14.3 mmHg.
  • Resolution was achieved with one intervention in 17 eyes; 10 required repeat procedures. Specific treatments included medical therapy (4 eyes), laser hyaloidotomy (7 pseudophakic eyes), VHI (4 eyes), and TSCPC (12 eyes).

Conclusions:

  • Malignant glaucoma can be successfully managed with appropriate and timely interventions.
  • Medical treatment is effective for phakic eyes; laser hyaloidotomy for pseudophakic eyes.
  • Vitrectomy and TSCPC are valuable for refractory cases, with a stepladder approach proving highly successful.